A group of researchers at the Institute for Research in Immunology and Cancer (IRIC) of Université de Montréal discovered a promising new approach to treating leukemia by disarming a gene that is responsible for tumor progression. ...
Feb 13, 2014
0
0
(Medical Xpress)—The American Brain Tumor Association says this year nearly 70,000 people in the United States will be diagnosed with tumors that form in blood vessels, cranial nerves, lymphatic tissue and other parts of ...
Feb 4, 2014
0
0
While ultrasound provides a less expensive and radiation-free alternative to detecting and monitoring cancer compared to technologies such as X-rays, CT scans, and MRIs, ultrasound has seen limited use in cancer treatment ...
Jan 29, 2014
0
1
Eight of 16 patients participating in a study of an experimental immune system therapy directed against the most aggressive malignant brain tumors – glioblastoma multiforme – survived longer than five years after diagnosis, ...
Nov 24, 2013
0
0
A team of scientists looking into the interplay of the immune system and cancer have found a link between a history of airborne allergies – in particular to plants, grass and trees – with risk of blood cancers in women.
Nov 23, 2013
0
0
A new study by an international team led by Dana-Farber Cancer Institute scientists provides the first statistically-based guidelines for determining whether a stem cell transplant is appropriate for older patients with myelodysplastic ...
Jun 24, 2013
0
0
A new study on how the progression of acute lymphocytic leukemia (ALL) is influenced by the bone marrow environment has demonstrated for the first time that targeting a specialized protein known as osteopontin (OPN) may be ...
Apr 15, 2013
0
0
Researchers at Moffitt Cancer Center have determined that the overexpression of microRNA-155 (miR-155), a short, single strand of ribonucleic acid encoded by the miR-155 host gene, promotes the growth of blood vessels in ...
Apr 3, 2013
0
1
Researchers from the Centre for Genomic Regulation (CRG) in Barcelona reprogramme lymphoma and leukaemia cells to halt their malignancy. Resulting cells remain benign even when no longer subjected to treatment and reduce ...
Apr 3, 2013
0
0
Researchers at Moffitt Cancer Center have completed a phase II clinical trial to determine the safety and efficacy of dasatinib for patients with higher-risk myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia, ...
Mar 21, 2013
0
0
